UNSPSC 51282134: Oximonam sodium

This classification denotes a beta-lactam antibiotic C12H14N5O6S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G274R51QFV, chemically known as acetic acid, 2-(((2s,3s)-3-(((2z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl)amino)-2-methyl-4-oxo-1-azetidinyl)oxy)-, sodium salt (1:1), but more generally known as oximonam sodium, which bears US NIH Compound Identifier 23663948. Most nations, for tariff and trade purposes, schedule oximonam sodium under HS 29419000 and SITC 54139.

As of Q4 2014, OXIMONAM SODIUM remains US FDA's Preferred Term for this commodity. Oximonam sodium bears US NLM identifiers UMLS ID C1882241 and NCI Concept Code C66267. SMILES: C[C@H]1[C@@H](C(=O)N1OCC(=O)[O-])NC(=O)/C(=N\OC)/C2CSC(N2)N.[NA+].

UNSPSC 51282134 Oximonam sodium is a Commodity code that nominally covers a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code tag shows minimal alignment with the code's stated scope. The Illinois Department of Public Health and Seminole County, Florida have posted opportunities tagged to this code, yet neither procurement involves oximonam sodium; instead, they cover broader pharmaceutical warehouse orders (doxycycline hyclate and ciprofloxacin hydrochloride in Illinois) and naloxone plus drug deactivation systems (in Florida). State and local health departments and county public health authorities appear to be the primary issuing bodies using this code, though the mismatch between the code definition and actual solicitation content suggests inconsistent code application by these jurisdictions. The scope of work actually being bought—emergency medications, preventive pharmaceuticals, and harm-reduction products—reflects public health operational needs rather than a specialized active ingredient procurement.

Activity under this code appears limited and geographically dispersed. Recent opportunities come from Illinois and Florida, posted in mid-2026 and mid-2023 respectively. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract to Chartwell Rx LLC through the MMCAP Infuse consortium on August 28, 2026 (Solicitation 26482DPHPREPDB53392, closed award, no open solicitation); Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries, response due July 26, 2023 (note: the due date predates the posted date, indicating a data anomaly in the source). The code shows no clear pattern of repeat activity, and the disconnect between nominal scope and actual procurement suggests vendors evaluating opportunities under this code should verify the actual commodity requirement before pursuing.